Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EBT (2019 - 2025)

Historic EBT for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to -$1.0 million.

  • Cyclerion Therapeutics' EBT rose 1081.56% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 million, marking a year-over-year increase of 3868.35%. This contributed to the annual value of -$3.6 million for FY2024, which is 7198.67% up from last year.
  • As of Q3 2025, Cyclerion Therapeutics' EBT stood at -$1.0 million, which was up 1081.56% from -$1.7 million recorded in Q2 2025.
  • Over the past 5 years, Cyclerion Therapeutics' EBT peaked at $502000.0 during Q4 2024, and registered a low of -$16.2 million during Q2 2021.
  • For the 5-year period, Cyclerion Therapeutics' EBT averaged around -$6.2 million, with its median value being -$4.5 million (2022).
  • As far as peak fluctuations go, Cyclerion Therapeutics' EBT plummeted by 3313.41% in 2023, and later surged by 12796.66% in 2024.
  • Quarter analysis of 5 years shows Cyclerion Therapeutics' EBT stood at -$14.3 million in 2021, then skyrocketed by 68.93% to -$4.5 million in 2022, then surged by 59.71% to -$1.8 million in 2023, then surged by 127.97% to $502000.0 in 2024, then plummeted by 300.4% to -$1.0 million in 2025.
  • Its last three reported values are -$1.0 million in Q3 2025, -$1.7 million for Q2 2025, and -$1.5 million during Q1 2025.